CBUS
Cibus, Inc.
CBUS offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR
Oscar Health, Inc.
OSCR has the edge over CBUS overall, supported by stronger fundamentals and lower modeled downside.
CBUS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
CBUS's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CBUS PE Valuation
CBUS has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
CBUS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect CBUS's revenue to grow, with its earnings and profitability holding steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
CBUS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.30 | +$2.03 |
| Q2 2026 | -$1.45 | +$9.07 |
| Q1 2026 | -$1.77 | +$9.28 |
| Q4 2025 | -$2.78 | +$8.05 |
| Q3 2025 | -$3.33 | +$26.78 |
| Q2 2025 | -$10.52 | +$13.55 |
| Q1 2025 | -$11.05 | +$14.93 |
| Q4 2024 | -$10.83 | +$19.48 |
CBUS is still losing money, but far less than before: $1.30 per share over the past year, against $68.00 at its worst in mid-2020.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over CBUS on earnings quality, reporting a profit while its opponent remains loss making.
CBUS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $800K | +30% |
| Q2 2026 | $994K | +6.5% |
| Q1 2026 | $1.7M | +63% |
| Q4 2025 | $1.1M | -13% |
| Q3 2025 | $615K | -63% |
| Q2 2025 | $933K | +11% |
| Q1 2025 | $1M | +90% |
| Q4 2024 | $1.2M | +9.9% |
CBUS's revenue is recovering but still below its 2020 peak: $800,000 last quarter, up 30% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1563% | +947 points |
| Q2 2026 | -1300% | +623 points |
| Q1 2026 | -721% | +3299 points |
| Q4 2025 | -2136% | -649 points |
| Q3 2025 | -2510% | +9514 points |
| Q2 2025 | -1923% | +640 points |
| Q1 2025 | -4020% | -635 points |
| Q4 2024 | -1487% | +22929 points |
CBUS's operating margin was −1563% last quarter, up 947 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over CBUS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over CBUS on profitability, with a higher operating margin.
CBUS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$9.3M | +$2.5M |
| Q2 2026 | -$9.4M | +$4.3M |
| Q1 2026 | -$11.6M | +$517K |
| Q4 2025 | -$13.5M | +$545K |
| Q3 2025 | -$11.8M | +$2M |
| Q2 2025 | -$13.7M | +$3.5M |
| Q1 2025 | -$12.1M | +$1.6M |
| Q4 2024 | -$14.1M | +$3.4M |
CBUS has burned cash in almost every quarter: −$44M over the past year, against −$52M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over CBUS on cash generation, producing positive trailing cash flow while its opponent burns cash.
CBUS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +137K shares |
| 1 year | +45% | +24M shares |
| 3 years | +7682% | +75.9M shares |
| 5 years | +10253% | +76.2M shares |
| Available history | +11620% | +76.2M shares |
CBUS has 77M diluted shares, up 45% from a year ago.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over CBUS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CBUS Net Leverage
CBUS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
CBUS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.5 | Neutral |
| Stochastic | 4.7 | Oversold |
CBUS's weekly RSI is 38 (neutral) and its Stochastic is 5 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CBUS PE vs Healthcare Sector
CBUS has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CBUS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.38 | 21% below |
| 20 week MA | $1.58 | 31% below |
| 50 week MA | $1.77 | 38% below |
| 100 week MA | $1.82 | 40% below |
| 200 week MA | $8.07 | 86% below |
CBUS is in a downtrend: it's below all five of its weekly moving averages, and 86% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over CBUS on trend strength, trading above more of its moving averages.
CBUS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $320.5 | $215.5 | -33% |
| 2021 | $215.5 | $111.5 | -48% |
| 2022 | $111.5 | $6.60 | -94% |
| 2023 | $6.60 | $19.6 | +198% |
| 2024 | $19.6 | $2.36 | -88% |
| 2025 | $2.36 | $1.70 | -28% |
| 2026 YTD | $1.70 | $1.09 | -36% |
CBUS's yearly returns have swung widely, from +198% in 2023 to −94% in 2022. It's down 36% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over CBUS on returns for 2026, with the stronger performance.